RELIEF THERAPEUTICS Holding SA

RELIEF THERAPEUTICS Holding SA, à Genève, CHE-113.516.874 (FOSC du 14.05.2024, p. 0/1006032049). Lock Michelle n'est plus administrateur;
ses pouvoirs sont radiés. Meinen Jeremy jusqu'ici avec une signature collective à deux signe désormais individuellement.

"Category: Notifications issued to company members/nSub-category: Invitation to the General Meeting/nPublication date: SHAB 03.06.2024/nPublicly viewable until: 03.06.2026/nPublication number: UP04-0000006372/nPublishing entity/nRELIEF THERAPEUTICS Holding SA, avenue de Sécheron 15.

1202 Genève/nInvitation to the ordinary general meeting RELIEF/nTHERAPEUTICS Holding SA/nOrganisation concerned:
/nRELIEF THERAPEUTICS Holding SA/nCHE-113.516.874/navenue de Sécheron 15/n1202 Genève/nGeneral meeting details:/n27.06.2024, 11.00 Uhr, Campus Biotech, chemin des Mines 9.

1202 Genève/nInvitation/Agenda:
/n1. Approval of the Annual Report 2023, Statutory Financial Statements and Consolidated/nFinancial Statements for the Financial Year 2023/n2. Appropriation of Results/n3. Discharge of the Board of Directors and the Executive Committee/n4.1 Vote on the compensation of the Board of Directors/n4.2 Vote on the remuneration of the Executive Committee/n4.3 Consultative vote on the 2023 Compensation Report/n5.1 Re-election of the current members of the Board of Directors/n5.2 Re-election of the Chairman of the Board of Directors/n5.3 Re-election and election of new members of the Nomination and Compensation/nCommittee/n5.4 Re-election of the Independent Voting Rights Representative/n5.5 Re-election of the Auditors/nTo the Shareholders of RELIEF THERAPEUTICS Holding SA:/nInvitation to the Annual Shareholders' Meeting/nof RELIEF THERAPEUTICS Holding SA/nThursday, 27 June 2024.

11:
00 a.m. CEST (door opening: 10:30 a.m. CEST)/nat Campus Biotech, chemin des Mines 9, 1202 Geneva, Switzerland/nThe Annual General Meeting of Shareholders of RELIEF THERAPEUTICS Holding SA (the ""Company"") will be/nheld in accordance with article 9 and subsequent articles of the Articles of Association on Thursday, 27 June/n2024.

at 11:
00 a.m. CEST at Campus Biotech, chemin des Mines 9, 1202 Geneva, Switzerland./nAgenda Items and Proposals of the Board of Directors/n1. Approval of the Annual Report 2023, Statutory Financial Statements and Consolidated/nFinancial Statements for the Financial Year 2023/nThe Board of Directors proposes the approval of the annual report 2023, the statutory financial statements/nand the consolidated financial statements for the financial year 2023./nExplanation: Pursuant to article 698 para. 2 al. 3 and 4 of the Swiss Code of Obligations (""CO""), the General/nMeeting is responsible for approving the annual report, the statutory financial statements and the/nconsolidated financial statements./n2. Appropriation of Results/nThe Board of Directors proposes to carry forward the loss for the financial year 2023 of CHF 39'943'547./nExplanation: Pursuant to article 698 para. 2 al. 4 CO, the General Meeting is responsible for the/nappropriation of results./n3. Discharge of the Board of Directors and the Executive Committee/nThe Board of Directors proposes that the General Meeting grants discharge to all current and former/nmembers of the Board of Directors and of the Executive Committee for the financial year 2023./nExplanation: Pursuant to article 698 para. 2 al. 7 CO, the General Meeting is responsible for the discharge/nresolution. The resolution for discharge presented to this General Meeting for the financial year 2023 serves/nas a supplementary action. It follows the initial discharge granted by the Extraordinary General Meeting/nheld on 26 April 2024, which occurred prior to the publication of the Company's 2023 annual report./n4. Votes on the compensation of the members of the Board of Directors and of the Executive/nCommittee/nThe Board of Directors proposes a separate vote on the compensation of the Board of Directors and of the/nExecutive Committee. The 2023 compensation report is included in the 2023 annual report, which can be/naccessed on the Company's website at www.relieftherapeutics.com./n4.1. Binding vote on the total compensation of the members of the Board of Directors for the period/nfrom the Annual General Meeting 2024 until the Annual General Meeting 2025/nThe Board of Directors proposes the approval of a maximum amount of CHF 1'000'000 (both fixed and/nvariable compensation, including stock options and other benefits, but excluding employer social security/ncontributions) for the members of the Board of Directors for the period from the Annual General Meeting/n2024 until the Annual General Meeting 2025./nExplanation: Pursuant to article 698 para. 3 al. 4 CO, the General Meeting is responsible for approving the/nmaximum compensation of the Board of Directors. The compensation of the Board of Directors is/ndetermined based on discretionary economic considerations and may be delivered in cash and in the form/nof options. A description of the Company's compensation principles and amounts for the members of the/nBoard of Directors can be found in the 2023 compensation report./n4.2. Binding vote on the total remuneration of the members of the Executive Committee for the financial/nyear 2025/nThe Board of Directors proposes the approval of a maximum total compensation of CHF 4'000'000 (both/nfixed and variable compensation, including stock options and other benefits, but excluding employer social/nsecurity contributions) for the members of the Executive Committee for the financial year 2025./nExplanation: Pursuant to article 698 para. 3 al. 4 CO, the General Meeting is responsible for approving the/nmaximum remuneration of the Executive Committee. The compensation of the members of the Executive/nCommittee consists of a fixed remuneration, a potential variable remuneration, and other benefits. A/ndescription of the Company's compensation principles and amounts for the members of the Executive/nCommittee can be found in the 2023 compensation report./n4.3. Consultative vote on the 2023 Compensation Report/nThe Board of Directors proposes that the General Meeting approves, on a consultative basis, the/ncompensation report for the financial year 2023./nExplanation: Pursuant to article 735 para. 3 al. 4 CO, the Board of Directors submits the compensation/nreport to the General Meeting for a consultative vote./n5. Elections/n5.1. Re-election of the current members of the Board of Directors/nThe Board of Directors proposes the re-election of the following members of the Board of Directors for/nanother term of office that will end for all members with the closure of the next Annual General Meeting./nThe re-elections will be held individually./na) Re-election of Dr. Raghuram Selvaraju/nb) Re-election of Ms. Michelle Lock/nc) Re-election of Mr. Peter de Svastich/nd) Re-election of Mr. Gregory Van Beek/ne) Re-election of Mr.

Thomas Elzinga/nExplanation:
Pursuant to article 698 para. 2 al. 2 CO, the General Meeting is responsible for the elections of/nthe members of the Board of Directors. Biographical details on the candidates are provided in the 2023/nannual report and on the Company's website at www.relieftherapeutics.com./n5.2. Re-election of the Chairman of the Board of Directors/nThe Board of Directors proposes the re-election of Dr. Raghuram Selvaraju as Chairman of the Board of/nDirectors for a term of office that will end with the closure of the next Annual General Meeting./nExplanation: Pursuant to article 698 para. 3 al. 1 CO, the General Meeting is responsible for the above/nelection./n5.3. Re-election and election of new members of the Nomination and Compensation Committee/nThe Board of Directors proposes the election of Mr. Peter de Svastich and the re-election of Dr. Raghuram/nSelvaraju as members of the Nomination and Compensation Committee for a term of office which will end/nwith the closure of the next Annual General Meeting. The elections will be held individually./nExplanation: Pursuant to article 698 para. 3 al. 2 CO, the General Meeting is responsible for the above/nelection. The elections of the members of the Nomination and Compensation Committee are held/nindividually./n5.4. Re-election of the Independent Voting Rights Representative/nThe Board of Directors proposes the re-election of Mr. Thomas Hua, esq., partner at gbf Avocats SA, Route/nde Pré-Bois 20, 1215 Genève Aéroport, Switzerland, as independent proxy holder of the Company for the/nnext term "

RELIEF THERAPEUTICS Holding SA, à Genève, CHE-113.516.874 (FOSC du 07.09.2023, p. 0/1005833513). Capital-actions réduit de CHF 56'163'348 à CHF 1'404'083, 70 pour supprimer un excédent de passif constaté au bilan, par réduction de la valeur nominale des 14'040'837 actions de CHF 4 à CHF 0.10.

Capital-actions:
CHF 1'404'083, 70, entièrement libéré, divisé en 14'040'837 actions de CHF 0.10, nominatives. Suppression de la clause relative à la marge de fluctuation du capital en application de l'art. 653v al. 1 CO. L'assemblée générale a supprimé le 26.04.2024 les clauses statutaires relatives à l'augmentation du capital au moyen d'un capital conditionnel introduites par décision du 28.04.2023. L'assemblée générale a introduit deux clauses statutaires relatives à l'augmentation du capital-actions au moyen d'un capital conditionnel par décision du 26.04.2024 (pour les détails, voir les statuts). L'assemblée générale a introduit une clause statutaire relative à une marge de fluctuation du capital-actions par décision du 26.04.2024;
pour les détails, voir les statuts (art. 3a ter). Statuts modifiés le 26.04.2024, ainsi que sur des points non soumis à publication. Plitz Thomas et Jean Patrice P. ne sont plus administrateurs;
leurs pouvoirs sont radiés. Meinen Jeremy est maintenant domicilié à Zug.

Nouveaux administrateurs:
De Svastich Peter, des USA, à New York, USA, Elzinga Thomas, des USA, à New York, USA, et Van Beek Gregory, des USA, à New York, USA, tous avec signature collective à deux.